Inovio Pharmaceuticals (NASDAQ:INO) is a biotechnology firm focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines for infectious diseases and cancer. The company leverages its proprietary plasmid DNA technology to stimulate robust and specific immune responses. Inovio's pipeline includes candidates for HPV-associated diseases, cancer, and infectious diseases such as COVID-19. With a commitment to global health, Inovio aims to innovate and make accessible new vaccines and therapies that can change the course of human diseases. Additionally, the company collaborates with industry leaders and organizations worldwide to advance and expand its reach in public health.